INDIVIDUAL TEST 355

Sulfatide Antibodies (IgM)

Indication

Suspicion of polyneuropathy

Sample material

Serum

• Minim. volume: 0,5 mL

CSF

• Minim. volume: 0,5 mL

Transport

Within Sweden

• room temperature

International

• cold

Method

ELISA

Reference interval

• < 10 negative, 10-15 borderline

Result

Results are reported as negative, borderline, or positive with a ratio.

Interpretation

IgM antibodies against sulfatide are predominantly present in patients with antibodies against myelin-associated glycoprotein (MAG) but isolated findings occur in cases with neuropathy. The clinical value is limited. IgM antibodies against sulfatide in CSF have low clinical value but have been reported in autoimmune disease conditions.

References

• Jacobs BC et al. IGOS Consortium. J Peripher Nerv Syst. 2017. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. PMID: 28406555
• Shang P et al. J Neurol. 2021. Axonal variants of Guillain-Barré syndrome: an update. PMID: 32140865
• Sheikh AB et al. J Neuroimmunol. 2021. Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review. PMID: 33895700
• Van den Bergh PYK et al. J Peripher Nerv Syst. 2021. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. PMID: 34085743
• Wijdicks EF, Klein CJ. Mayo Clin Proc. 2017. Guillain-Barré Syndrome. PMID: 28259232
• Willison HJ et al. Lancet. 2016. Guillain-Barré syndrome. PMID: 26948435

Last updated: 2025-06-02